Cannathemag
  • News
  • Magazine
  • Advertising
  • About Us
  • Language Services
  • Contacts
  • Search
  • CZ
Facebook Instagram

Safety and efficacy of cannabis oils in multiple sclerosis

22. April 2021 | Rubrika: Research Reports
Source: Unsplash.com

Source: Unsplash.com

In this observational safety study, a team of scientists from the Danish Multiple Sclerosis Center and the Department of Neurology at the University of Copenhagen, Denmark, monitored 28 patients with multiple sclerosis (MS).

They were treated with medical cannabis oils (THC-rich, CBD-rich and THC+CBD in equilibrium). The average dose was 4 milligrams for THC and 7 mg for CBD. The patients were undergoing neurological and other examinations during the four-week treatment. 

Pain decreased from average 7 to 4 points on the NRS-11 numeric rating scale, spasticity from 6 to 2.5 pts, and sleep disturbances from 7 to 3 pts, on average.

Treatment with medical cannabis oils was safe and well tolerated, and resulted in a reduction in pain intensity, spasticity and sleep disturbances in MS patients.

Side effects (dry mouth, drowsiness, dizziness, nausea) were reported when using the THC-rich oil but evaluated as moderate.

The authors of the study came to the conclusion that “treatment with medical cannabis oils was safe and well tolerated, and resulted in a reduction in pain intensity, spasticity and sleep disturbances in MS patients. This suggests that medical cannabis oils can be used safely, especially at relatively low doses and with slow titration, as an alternative to treat MS-related symptoms when conventional therapy is inadequate.”

Author: Tibor Béres

Source: Cannabis Therapy Vol. 2

Take a quick look at this preview of the contents:

Feel free to read, share and download here. Enjoy!

Ohodnoťte tento článek

You might like

  • Zdroj: Pexels.com Research Reports

    Successful clinical use of CBD-rich extracts in Covid-19 patients

  • Source: Unsplash.com Research Reports

    THC helps mitigate repeated mild brain injuries

  • Source: Pixels.com Research Reports

    THC derivative reduces intraocular pressure

1 Comment

  • adriaanbb says: 23. September 2023 at 20:24

    voor jespers vriend

    Reply
  • Write comment Cancel

    Search

    Latest News

    • Zdroj: unsplash.com

      Superior Treatment: Cannabis Extracts in Suppositories

      19. May 2025
    • Europe’s Largest Cannabis B2B Conference Is Coming Back To Berlin in One Week!

      22. April 2025
    • Source: Cannabis Embassy

      Centenary of Cannabis Prohibition: Global Cannabis History Year

      27. February 2025
    • Bern

      Join us in Bern for the largest European conference on medical cannabis

      21. January 2025
    Facebook YouTube SoundCloud
    • Advertising
    • Magazine
    • About Us
    • Contacts
    • Terms and Conditions

    CANNABIS THERAPY

    Magazine about medical uses of cannabis. For patients, health professionals as well as general public. Free of charge.

    Contact: office@konomag.cz

    Tel.: +420 737 300 375

    CATEGORIES

    • Advice
    • Breaking News
    • Experimental Treatment
    • Health
    • Inspiration
    • Interviews
    • Leaves of Grass
    • News
    • Pharmacopeia
    • Pharmacopoeia
    • Press Release
    • Research Reports
    • Uncategorized
    • Veterinary Medicine

    LATEST NEWS

    • Zdroj: unsplash.com

      Superior Treatment: Cannabis Extracts in Suppositories

      19. May 2025
    • Europe’s Largest Cannabis B2B Conference Is Coming Back To Berlin in One Week!

      22. April 2025

    SEARCH

    Follow us

    Facebook Instagram
  • © 2018-25 CANNABIS THERAPY magazine. All rights belong to their respective owners. Without their written consent it is prohibited to use parts or whole works in any way, particularly spreading and copying, mechanically or electronically, in English, Czech or any other language.

  • Cannathemag

    Manage consent to cookies and confirm your age
    We use technologies such as cookies to store and/or access device information. We do this to improve your browsing experience and display personalized ads. Consenting to these technologies will allow us to process data such as browsing behavior or a unique ID on this website. Disagreeing or withdrawing consent may adversely affect certain features and functions.

    This website also requires you to be of legal age. By accepting your preferences, you verify you are at least 18 years old.
    Functional Always active
    Technical storage or access is absolutely necessary for the legitimate purpose of enabling the use of a specific service that the subscriber or user has expressly requested, or for the sole purpose of carrying out the transmission of a message via an electronic communications network.
    Preferences
    The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
    Statistics
    Technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
    Marketing
    Technical storage or access is necessary to create user profiles in order to send advertising or track the user across a website or several websites for similar marketing purposes.
    Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
    Show preferences
    {title} {title} {title}
    Are you 18+?

    This website requires you to be of legal age. By clicking Yes, you verify you are at least 18 years old.